Panacea Biotec’s Easyfive TT Vaccine Order Analyzed
Panacea Biotec, an Indian vaccine company, has secured a significant order from the Pan American Health Organization (PAHO) for its Easyfive TT vaccine. This order is valued at $4.75 million (approximately Rs 41 crore). The Easyfive TT vaccine is designed to protect people from serious illnesses like diphtheria, whooping cough, and tetanus.
Key Points
- PAHO ordered $4.75 million Easyfive TT vaccine supply.
- Easyfive TT protects against diphtheria, Hib, Hepatitis B, etc.
- Supply will occur over 2026 and 2027 calendar years.
- Panacea Biotec is a leading Indian vaccine research company.
- Q1 FY26 profit increased to Rs 4.05 crore compared to a loss.
- Company revenue rose 44.1% year-on-year to Rs 166.70 crore.
This new contract shows that Easyfive TT is a well-regarded vaccine on a global scale. Panacea Biotec’s performance has dramatically improved in the last quarter. Their revenue and profits have shown a strong upward trend, indicating growing demand for their products.
Panacea Biotec’s recent financial results are promising. The company’s Q1 FY26 results demonstrated substantial growth in revenue and profitability. This success can be attributed to the growing demand for their vaccines, especially the Easyfive TT vaccine.
The company’s stock price also reflects this positive momentum, decreasing 2.24% to Rs 396.40 on November 11, 2025. This indicates that investors are confident in Panacea Biotec’s future prospects.
Successfully executing this global order confirms Panacea Biotec’s commitment to improving public health.
